18 and older, any sex, with Non-Ischemic Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Safety Will be Evaluated by Number of AEPrimary· Total AEs and SAEs within 450 days post-infusion
As identified in the SAP, the safety analysis was the primary objective and was evaluated by the number of AEs
Adverse Events
Group
Value
95% CI
Experimental
38
Placebo
35
Serious Adverse Events
Group
Value
95% CI
Experimental
1
Placebo
1
Cell related adverse events
Group
Value
95% CI
Experimental
1
Placebo
0
All-cause hospitalization
Group
Value
95% CI
Experimental
0
Placebo
0
All-cause death
Group
Value
95% CI
Experimental
0
Placebo
0
Change in LVEF From Baseline to Day 90 Post-initial Infusion.Secondary· Baseline to Day 90
The secondary efficacy endpoint was the change in LVEF from baseline to Day 90 post-initial infusion. Participants with data available at each time point.
Baseline (%)
Group
Value
95% CI
Experimental: Human (itMSC)
34.3
± 7.91
Placebo:Lactated Ringer's Solution (LRS)
34.5
± 7.49
90 days (%)
Group
Value
95% CI
Experimental: Human (itMSC)
34.1
± 9.7
Placebo:Lactated Ringer's Solution (LRS)
36.7
± 5.42
Adverse events — posted to ClinicalTrials.gov
Time frame: 450 days.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Experimental
Serious: 1/22 (5%)
Deaths: 0/22
Placebo
Serious: 1/20 (5%)
Deaths: 0/20
Serious adverse events (1 terms)
Reaction
System
Experimental
Placebo
atrial fibrillation
Cardiac disorders
—
—
Other adverse events (7 terms — click to expand)
Reaction
System
Experimental
Placebo
General Disorders and administration site condition: chest pain, fatigue, pyrexia
A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CardioCell LLC
Last refreshed: 7 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02467387.